Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 November 2024 | Story André Damons | Photo Supplied
Dr Emmanuel Arko-Cobbah
Dr Emmanuel Arko-Cobbah, Senior Lecturer and Medical Specialist in the Department of Surgery at the University of the Fee State (UFS) and a trauma surgeon, has recently been inducted as a Fellow of the American College of Surgeons (ACS).

Dr Emmanuel Arko-Cobbah, Senior Lecturer and Medical Specialist in the Department of Surgery at the University of the Fee State (UFS), says he hopes his induction as a fellow of the American College of Surgeons (ACS), will show the world that South Africa also produces great doctors from whom they can learn.

The ACS is dedicated to improving the care of the surgical patient and safeguarding standards of care in an optimal and ethical practice environment. Dr Arko-Cobbah was inducted on 19 October after a rigorous process. He was part of 1 800 candidates from around the world, but mostly from North America, with about 600 from other countries outside of the US and Canada.

Dr Arko-Cobbah, a trauma surgeon, says it feels surreal as it has always been his dream to become a Fellow of the American College of Surgeons, although it often felt like an impossible dream. “I truly thank God, and I am very grateful, because to me, it feels like it's all part of His plans for me, that is why He is making these things possible for me.

“As a trauma surgeon, it makes me feel I have achieved even beyond our borders, and it gives me the opportunity to also share the knowledge we have locally with the rest of the world. We have a lot to offer, but we tend to get underestimated because of where we’re from,” says Dr Arko-Cobbah.

To become a fellow of the ACS, applicants go through a selection process after applying and then they need to be nominated by three different fellows of the American College who are in good standing. If their nominations get accepted, an interview follows whereafter the reports are reviewed by the committee which then decides the outcome.

South Africa produces great doctors

According to Dr Arko-Cobbah, he hopes to put the UFS on the map with this lifelong fellowship so that the world can know South Africa also produces great doctors and that they can learn from these doctors. “The other side of the coin is for me to inspire others to also aim to get into the American College, and to dream even bigger than this. If I could do this, then anybody can. Partner with God, and dream big dreams, and make big plans. That is what I was taught by Pastor At Boshoff since I was a student, and God has always been faithful.”

After qualifying as doctor and becoming a general surgeon at the UFS, and super specialised as a trauma surgeon, Dr Arko-Cobbah completed a Surgical Leadership Programme with Harvard University in Boston, in the US. “God has always been good to me, and I am forever grateful to the support of my wife and family and continued inspiration and mentorship from Prof André Loubser. I am grateful to the late Prof Theron, and the UFS Surgery Department, past and present, for always pushing me to be better. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept